Theranostics at Astera Cancer Care
What is Theranostics?
Theranostics is a groundbreaking FDA-approved approach in cancer care that combines diagnostics and therapeutics into a single procedure. This innovative method involves using advanced imaging techniques to locate cancer cells anywhere in the body and then deliver targeted radiation to eliminate those cells. Positron Emission Tomography (PET) is used to detect the cancer, followed by an infusion of medication to destroy it. The precision of theranostics minimizes damage to surrounding healthy tissues, making it a highly effective treatment option.
Advances in Theranostic Procedures
Recent medical advancements have led to an increase in FDA-approved theranostic procedures in the United States. Physicians at the forefront of this field have significantly contributed to clinical trials and research, driving the development of new and promising theranostic treatments.
How Does Theranostics Work?
Theranostics employ radiotracers—compounds composed of radiation and drugs that bind to specific targets in the body. A pair of radiotracers, differing only in the type of radiation they emit, are used for diagnosis and treatment. During the diagnostic phase, a low-radiation radiotracer identifies cancer cells. For treatment, a similar radiotracer with a more potent radioactive component is used to kill the cancer cells. This targeted approach ensures that healthy cells remain largely unaffected.
Who is Eligible for Theranostics?
Theranostics is typically recommended for patients with metastatic disease that has not responded well to conventional therapies such as chemotherapy. Eligibility is determined through a PET scan to identify if the radiotracers can target the tumor. If the tumor is widespread and can be targeted, the patient may proceed with theranostic treatment. For localized tumors, alternative treatments like surgery or external beam radiation may be more appropriate.
Types of Cancer Treated with Theranostics
Theranostics has proven effective for various types of cancer, including:
- Thyroid Cancer: Radioactive iodine tracers, administered as a pill or liquid, have been used successfully for decades.
- Neuroendocrine Tumors: Lutathera (Lu 177 dotatate) targets somatostatin receptors on tumor cells.
- Prostate Cancer: Pluvicto (Lu 177 vipivotide tetraxetan PSMA) treats advanced prostate cancer resistant to other therapies. Xofigo (Ra 223) treats patients with metastatic prostate cancer that has spread to bones.
Benefits of Theranostic Medicine
While theranostic treatments may not cure cancer, they can significantly extend patients' length and quality of life. These treatments are generally well-tolerated and can alleviate symptoms caused by cancer, offering a valuable alternative when other therapies are ineffective.
Potential Side Effects
Patients may experience side effects due to radiation exposure, which can slightly increase the risk of developing other cancers. Common side effects include temporary decreases in certain blood cell levels, fatigue, dry mouth, and gastrointestinal symptoms like nausea. Regular monitoring ensures any side effects are managed effectively.
The Theranostic Procedure
First, a PET scan is performed to locate cancer cells. Based on these results, a follow-up treatment with a targeted radiotracer is administered to kill the cancer cells. The infusion typically takes a few minutes, followed by a brief observation period before the patient can go home. The radiation is naturally eliminated from the body within a few days.
Why Choose Astera Cancer Care for Theranostic Treatment?
Astera Cancer Care is at the forefront of theranostic treatment, with a team of expert physicians and scientists dedicated to advancing this innovative approach. Astera is also a leader in clinical trials and research, including the use of novel theranostic drugs to treat various cancers.